Guardant Health (NASDAQ:GH) Given New $34.00 Price Target at Piper Sandler

Guardant Health (NASDAQ:GH) had its target price increased by Piper Sandler from $30.00 to $34.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 11.73% from the company’s current price.

GH has been the subject of a number of other reports. The Goldman Sachs Group raised their price objective on Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. BTIG Research lifted their target price on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Guggenheim raised Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Friday, June 28th. Canaccord Genuity Group increased their price objective on Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Finally, Craig Hallum boosted their price objective on shares of Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.27.

Guardant Health Stock Down 0.1 %

Shares of GH traded down $0.04 during midday trading on Tuesday, hitting $30.43. The stock had a trading volume of 609,334 shares, compared to its average volume of 2,044,129. The company has a debt-to-equity ratio of 16.70, a current ratio of 5.95 and a quick ratio of 5.66. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of -7.76 and a beta of 1.13. The company has a 50 day simple moving average of $30.65 and a two-hundred day simple moving average of $24.10. Guardant Health has a twelve month low of $15.81 and a twelve month high of $41.06.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The business had revenue of $177.24 million for the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.67) earnings per share. On average, analysts anticipate that Guardant Health will post -3.31 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GH. Van ECK Associates Corp grew its stake in Guardant Health by 29.4% in the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after purchasing an additional 614 shares during the period. Principal Financial Group Inc. boosted its stake in Guardant Health by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock valued at $353,000 after acquiring an additional 1,240 shares during the last quarter. Wealthcare Advisory Partners LLC grew its position in shares of Guardant Health by 17.9% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 8,596 shares of the company’s stock valued at $233,000 after acquiring an additional 1,308 shares during the period. Oak Ridge Investments LLC increased its stake in shares of Guardant Health by 8.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock worth $382,000 after purchasing an additional 1,451 shares during the last quarter. Finally, Headlands Technologies LLC raised its holdings in shares of Guardant Health by 362.3% in the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after purchasing an additional 1,844 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.